Purpose Uncertainty exists about whether elderly patients benefit to the same extent as
younger patients from combination therapy with irinotecan in the first-line treatment of …

BACKGROUND: Irinotecan‐based chemotherapy regimens are 1 option for treatment of
metastatic colorectal cancer (mCRC). The authors report the safety and efficacy of such …

Purpose Elderly patients constitute a subpopulation with special characteristics that differ
from those of the nonelderly and have been underrepresented in clinical trials. This study …

Purpose: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with
bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV)(FOLFIRI regimen) …

Background Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients.
However, data from a geriatric tailored randomized trial about tolerance to and the efficacy of …

Background Recently published population-based investigations showed elderly patients to
be underrepresented in clinical trials and less often treated according to the standard …

Background Elderly and frail patients with cancer, although often treated with chemotherapy,
are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose …

Purpose The tumor-activated fluoropyrimidine capecitabine achieves response rates
superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for …

PURPOSE: Healthy elderly patients with metastatic colorectal cancer may benefit from
chemotherapy as much as the younger population. This analysis compares the outcomes of …

Elderly patients are recommended to have a reduced starting dose (300 mg m− 2 once
every 3 weeks) of irinotecan monotherapy. The aims of this analysis are to compare toxicity …